Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Clinical trial NCT03379493 · TERMINATED
Trial details
- NCT number
- NCT03379493
- Sponsor
- Eureka Therapeutics Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-04
- Primary completion
- 2018-12-23
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.